LOGO:National Chiayi University * ::: * Home *| * Sitemap *| * FAQ *| * Contact us *| * Bilingual *| * Chinese *
*
**
*::: User Identity  
* * Freshmen
*
* * Students
*
* * Faculties
*
* * Staffs
*
* * Alumni
*
* * Visitants
* News Express  
* * News
*
* * Bulletin
* About NCYU  
* * Visitors
*
* * NCYU Video
*
* * International Students Admission
*
* * Departments & Colleges
*
* * Administration
*
* * Calendar
* Services  
* * Campus Life
*
* * E-campus
*
* * Knowledge
*
* * Careers
*
* * FAQ
*
* * Law and Rules
*
* * Statistics
*
* * Bilingual Terms
*
* * Vote

* 嘉義大學華語組
*
NCYU Podcast
*
  more banner
*
*

* *
* *
* Visited:5086535
* Update:2022/05/06
* Now:2022/08/15 08:56
*
* Privacy
*
* Security

Orchid Spider lily Slender goldshower
* :::* Home > News
*  
 
* News *
Browsing: 279 times

Date:2022-06-17
Bracket:2022 NCYU NEWS
Department:ncyu

 A group photo of NCYU President Han Chien Lin (in the middle) with Pro. Yi-Wen Liu of the Department of Microbiology, Immunology and Biopharmaceuticals (third from left), Associate Prof. Geng-Ruei Chang of the Department of Veterinary Medicine (second from right) and their research teams. NCYU and Chang Gung Memorial Hospital, Linkou, Contribute to Clinical Medicine through Breakthroughs in Treating Lung Large-Cell Carcinoma
  Each year, lung cancer accounts for more than one million deaths in the world, and nearly 10,000 deaths in Taiwan, where it has become one of the deadliest cancers. The lung large-cell carcinoma is the most incurable type of lung cancer with a mortality rate of over 50%. Associate Prof. Geng-Ruei Chang’s team from the Department of Veterinary Medicine, National Chiayi University, and Dr. Ching-Feng Wu and Dr. Ching-Yang Wu’s team from the Division of Thoracic Surgery, Chang Gung Memorial Hospital, Linkou, have joined hands to conduct research on treating lung large-cell carcinoma. After over 2 years of experiments, cyanidin 3-O-glucoside, an anthocyanin, is found to effectively inhibit the tumor growth and tumor growth microenvironment in lung large-cell carcinoma. This can in turn facilitate the apoptosis of lung large-cell carcinoma, increase the patient’s survival rate, and inhibit the metastasis of lung large-cell carcinoma. This year, the research results were published in the latest June issue of the world-renowned journal Biomedicine & Pharmacotherapy, and have been highly regarded in the medical community at home and abroad.

  According to Prof. Yi-Wen Liu of the NCYU Department of Microbiology, Immunology and Biopharmaceuticals, also one of the authors of the paper, the study was published in the journal Biomedicine & Pharmacotherapy is a testament to the recognition of Taiwan’s medical research by the international academic community. Biomedicine & Pharmacotherapy ranks among the top 10% of international journals on pharmacology. Among the hundreds of pharmacology journals in the world, only the top 20 can enter the top 10% rankings. Annually, less than 100 papers from around the world are selected for publication in the journal. This study demonstrated the therapeutic potential of cyanidin 3-O-glucoside to treat lung large-cell carcinoma via the mTOR pathway. If given an opportunity to enter clinical trials, it is expected to become a new drug for lung cancer in the future.

  Dr. Ching-Feng Wu, a thoracic surgeon at Chang Gung Memorial Hospital, Linkou, mentioned that it has been known that lung cancer is not caused by a single factor, and shows a tendency to onset at a younger age. Lung cancer can be attributed to smoking, involuntary smoking, and air pollution, among others; and lung large-cell carcinoma mostly occurs in males. It can grow rapidly and is highly metastatic. Most patients have entered advanced stage when diagnosed with malignant cancer, and mostly cannot undergo resection. What’s more tricky is that lung large-cell carcinoma has grown resistant to conventional chemotherapy drugs, leading to a 3-year survival rate of less than 10% for patients with distantly metastatic lung large-cell carcinoma.

  NCYU President Han Chien Lin stated that the College of Veterinary Medicine, College of Life Sciences and other colleges of the unversity often cooperate with a number of medical centers and teaching hospitals in Taiwan, including Chang Gung Memorial Hospital, Linkou, Taichung Veterans General Hospital, Chang Bing Show Chwan Memorial Hospital and Chia-Yi Christian Hospital. Their research results have often been published in internationally renowned medical journals. The collaboration of NCYU with major hospitals in making breakthroughs in clinical medicine bears witness to the university’s dynamic research capacity. While clinical medicine is not the only pursuit for modern medical training, having a solid background in basic research helps meet the needs of clinical medicine. There is a long-standing lack of medical resources and universities with medical departments in the Yunlin and Chiayi region, where NCYU is located. Complete with diverse learning resources as a comprehensive university, NCYU aims to put into practice the concept of holistic medicine, and nurture medical professionals meeting the needs of the new generation, thus fulfilling the social responsibility as a university.

After the lung large-cell carcinoma was treated with cyanidin 3-O-glucoside, an increase of tumor cell death was observed (an increase in green fluorescence, as shown in the top right picture); a 3D view of the tumor showed that the lung cancer tumor became significantly smaller (as shown in the bottom right picture). The tumor in the nude mice shrank significantly after being treated with cyanidin 3-O-glucoside.
*

*


top
*
* * *
back


* LOGO:National Chiayi University  Copyright © 2020 National Chiayi University

No.300 Syuefu Rd., Chiayi City 600355, Taiwan (R.O.C.)
Tel: TEL: +886-5-2717000 FAX: +886-5-2717095
Privacy|Security

 

[ logo][logo gov]